# A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis

> **NCT07234591** · NA · RECRUITING · sponsor: **Usynova Pharmaceuticals Ltd.** · enrollment: 140 (estimated)

## Conditions studied

- Plaque Psoriasis
- Moderate to Severe Plaque Psoriasis

## Interventions

- **DRUG:** Tyk2 inhibitor
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07234591
- **Lead sponsor:** Usynova Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-21
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-05-30
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07234591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07234591, "A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT07234591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*